Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: Focus on vildagliptin

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 161-170

  Russo, Eleonora ^a   Penno, Giuseppe ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chronic kidney disease; Renal function; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MYELOPEROXIDASE; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; VILDAGLIPTIN; XANTHINE OXIDASE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; COUGHING; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RELEASE; KIDNEY FAILURE; LIPID PEROXIDATION; LIVER DISEASE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84876543147     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S28951     Document Type: Review

References (49)

1. American Diabetes Association. Standard of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
2. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378: 182-197.
3. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303: 1410-1418.
4. Gross JL, Kramer CK, Leitão CB, etal; for Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011;154:672-679.
5. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1-S266.
7. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608-2617.
8. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust. 2006;185:140-144.
9. Penno G, Solini A, Bonora E, etal; for Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29:1802-1809.
10. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12:57-69.
11. Moen MF, Zhan M, Hsu VD, etal. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4: 1121-1127.
12. Shurraw S, Hemmelgarn B, Lin M, etal; for Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171: 1920-1927.
13. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34: 1431-1437.
14. Fonseca VA. Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr Vivian A Fonseca. Am J Med. 2011;124(Suppl 1):S54-S61.
15. Lee S, Bilous R. STARDUST-study of the treatment and prevalence of renal disease in UK diabetes mellitus type 2 patients. Diabetologia. 2011;54(Suppl 1):S128, A293.
16. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51:147-162.
17. Pratley RE, Rosenstock J, Pi-Sunyer FX, etal. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017-3022.
18. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4inhibitors: similarities and differences. Drugs. 2011;71:1441-1467.
19. Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother. 2012;13:1377-1384.
20. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012;3:8.
21. Foley JE, Bunck MC, Möller-Goede DL, etal. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. 2011;54: 1985-1991.
22. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29: 14-25.
23. Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37:386-398.
24. Arjona Ferreira JC, Marre M, Barzilai N, etal. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. Epub December 17, 2012.
25. Nowicki M, Rychlik I, Haller H, etal. Long-term treatment with the dipeptidyl peptidase-4inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65:1230-1239.
26. Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010;90: 182-190.
27. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11:804-812.
28. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495-509.
29. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population $ 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13:55-64.
30. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-954.
31. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97:3799-3806.
32. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485-494.
33. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14:1032-1039.
34. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103-3109.
35. Ito M, Abe M, Okada K, etal. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011;58:979-987.
36. Nakata H, Sugitani S, Yamaji S, etal. Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease. Intern Med. 2012;51:3045-3049.
37. Arjona Ferreira JC, Corry D, Mogensen CE, etal. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. Epub January 23, 2013.
38. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009;40: 536-544.
39. Gonçalves A, Leal E, Paiva A, etal. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab. 2012;14:454-463.
40. Ojima A, Ishibashi Y, Matsui T, etal. Glucagon-like Peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol. 2013;182:132-141.
41. Li W, Cui M, Wei Y, Kong X, Tang L, Xu D. Inhibition of the expression of TGF-ß1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem. 2012;30:749-757.
42. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP-4inhibitors-from preclinical development to clinical research. Kidney Blood Press Res. 2012;36:65-84.
43. Liu WJ, Xie SH, Liu YN, etal. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248-255.
44. Vaghasiya J, Sheth N, Bhalodia Y, Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept. 2011;166:48-54.
45. Glorie LL, Verhulst A, Matheeussen V, etal. DPP-4inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2012;303:F681-F688.
46. Wang Y, Landheer S, van Gilst WH, etal. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE-and DPP4-inhibitory Activity. PLoS One. 2012;7:e46781.
47. Groop P-H, Cooper M, Perkovic V, etal. Effects of the DPP-4inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy. Diabetologia. 2012;55(Suppl 1):S20, A36.
48. Hung AM, Roumie CL, Greevy RA, etal. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81:698-706.
49. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond). 2013;124:17-26.